Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 10/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | CDK7 | P50613 | 2/20 | 0.34 |
| ▸ | CCNH | P51946 | 2/20 | 0.34 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | IGF1R | P08069 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | FLT4 | P35916 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.33 |
| ▸ | TEK | Q02763 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21178225 | 1.00 | DGAT1 (0.43) | DGAT1PTPN1CDK7CCNHMNAT1 | |
| SCHEMBL28312445 | 0.87 | CCNT1 (0.44) | DGAT1PTPN1CDK7CCNHMNAT1 | |
| SCHEMBL21184412 | 0.87 | DGAT1 (0.38) | DGAT1PTPN1CDK7CCNHMNAT1 | |
| SCHEMBL25421692 | 0.85 | DGAT1 (0.38) | DGAT1PTPN1CDK7CCNHMNAT1 | |
| SCHEMBL21184629 | 0.84 | DGAT1 (0.43) | DGAT1PTPN1CDK7CCNHMNAT1 | |
| SCHEMBL30771939 | 0.84 | DGAT1 (0.43) | DGAT1PTPN1CDK7CCNHMNAT1 | |
| SCHEMBL21184311 | 0.82 | CDK7 (0.50) | CDK7CCNHMNAT1CCNT1CDK9 | |
| SCHEMBL25225754 | 0.80 | DGAT1 (0.41) | DGAT1CDK7CCNHMNAT1 | |
| SCHEMBL29498421 | 0.80 | DGAT1 (0.41) | DGAT1CDK7CCNHMNAT1 | |
| SCHEMBL21184310 | 0.80 | CDK7 (0.43) | DGAT1CDK7CCNHMNAT1CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220305014-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2022-09-29 | — | — | US | disclosed |
| US-11311542-B2 | Inhibitors of cyclin dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11311542-B2 | Inhibitors of cyclin dependent kinase 7 (CDK7) | CDK7, CDK3, CCNK | DGAT1 2288/4885PTPN1 3596/4885CDK7 1/4885 |
| US-20220305014-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CCNK | DGAT1 2288/4885PTPN1 3596/4885CDK7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.